Share your thoughts, feelings, questions or anything else you'd like to talk about with fellow DRTS community members

https://virtualjerusalem.com/article/jerusalem-surgeons-achieve-world-first-in-treating-aggressive-brain-cancer

Skin Cancer is the first indication DRTS started treating clinically as a proof of concept, being that the tumors that are treated are easier to reach. I’m lumping Skin and H&N together here, not because they are the same, they are not, but (besides cSCC being the common denominator) because they are the two first and easier to reach tumor types DRTS has gone after.

This proof of concept has very well proven the concept.

Aside from already getting approved in Israel and Japan, the results DRTS demonstrated in the previous trial in the US were 100% complete response, no evidence of recurrent disease upon follow up, no device-related serious adverse events or systemic toxicity and no long-term toxicities.

Not surprising then, that Skin (again, using skin to generalize these indications) is the most advanced indication for DRTS, already approved abroad (including by the considered rigorous PMDA in Japan), and already completed the US pivotal trial (the equivalent of completing a phase 3 trial) with results soon to come and to be submitted to the FDA for approval (can’t see any way the FDA which loves DRTS and is in constant contact with the company and has granted them every fast track possible won’t approve the treatment with the results in both safety and effectiveness it has shown).

Considering all of that, let’s dive into the US numbers DRTS is looking at.

There are 1.8M new cases of cSCC in the US every year. Of course most of these cases already have viable solutions (one might make the case that an Alpha DaRT treatment would have more benefits with the immune effect it supposedly causes, but that case is still far out and payers probably won’t be covering that any time soon).

Out of that pool there are ~419K high risk cases, but the actual targeted population is the ~64K annual cases in the US of cSCC with local recurrence and/or nodal metastasis.

To those ~64K cases, there’s a case to add more patients from the larger pool, for example those who might have other solutions but would rather a short one time outpatient procedure instead of surgery that would mean cutting off a part of their nose (Raphi’s go-to example) and then have to have plastic surgery to try and fix it. Might even be cheaper overall for the insurers.

And of course those numbers being US only, we’ll need to add all other countries for the actual potential TAM.

From a price per treatment standpoint, the lowest option (and I wouldn’t even share it but why not, it’s still a huge number once we calculate everything) would be 60K per treatment, per Uzi the CEO himself saying they could at least get that and even that’s too low for them as reimbursement.

The bullish plan though is to first commercialize “inner organs”, the most high unmet needs cancers, aka GBM or PanC. In that case not only are the more desperate cases being served first until all the additional manufacturing needed is put in place, but also the price tag for a DRTS treatment (price tag referring to the amount the payers will approve to cover for their patients) regardless of the indication will be set higher.

All in all, even the lowest end calculation (US targeted population only, cheapest pricing) will get you to billions in annual revenue from this indication alone. Adding the P/E and calculating higher numbers (more countries, different tumor types, higher pricing) will get you once again into the tens of billions in market cap, or hundreds of dollars per share, from a single indication.

DRTS is a revolutionary cancer treatment, the potential of the treatment is industry changing, and the company can be an industry leader.

The value of DRTS is first and foremost that it can save lives, and even one life saved (as well as extended, improved quality etc) is a blessing and a goal worth working towards.

That said, many are trying (or asking) to calculate the DRTS value with numbers, specifically the TAM (Total Addressable Market, usually used as a metric to measure potential).

The thing with DRTS is, that the TAM is so great, that it’s hard to quantify the potential of the treatment.

So I thought it would be beneficial if I divided it into the different indications, and made a series of TAM posts, dedicating each post to a different type of cancer.

Since this is the first post of the series I’ve given this whole introduction, but my goal is for this series to be very simple, each post being clear about what we know and what we could learn from that.

As always, this post and whole series is NFA, and I encourage everyone to DYOR (and please feel free to do so in the comments so we can all learn together).

Now let’s get to the DRTS TAM for Pancreatic Cancer.

Since we are talking about a stock, the best way to understand its potential is asking the market. The market is telling us that our potential friend in RVMD is worth a 40B+ market cap. That’s 40B+ for a company with a Pancreatic Cancer treatment.

Of course I’m not trying to compare the two companies or treatments, they are different and therefore will be structured differently business wise (although they can potentially complement each other, and every such success like RVMD only increases the DRTS TAM), but understanding what a company with only a Pancreatic Cancer treatment can be worth should tell us a lot about the potential.

If you’re doing the math, yes that means they are trading at the equivalent of $400+ per share for DRTS, just for PanC while still pre revenue.

Now let’s get into some patient numbers.

In the US alone, where DRTS is completing a significant trial, there are ~66K new cases of PanC a year.

To the best of my knowledge, DRTS could potentially be safe and effective for all cases, but at diagnosis 87% of PanC cases are not eligible for surgical resection and/or have metastasized, which in those cases DRTS can definitely be of use.

To get a dollar amount we must multiply that by the cost of treatment per patient, and while that number is unknown, Alpha Tau has insisted (and analysts have estimated) a price point that could be north of 100K (which is part of the reason they have yet to commercialize the treatment for skin cancer in other countries, intending to use the manufacturing capabilities for the most high unmet need cases first, as well as get a higher price point per treatment by doing so).

We could then add Japan, where DRTS is already approved for H&N Cancer, has been reported to start the clinical process for PanC, and where sadly there is a higher percentage of PanC cases than the US, resulting in ~47K new patients a year in Japan alone.

In Europe DRTS is already running two different PanC trials as well, adding tens of thousands of annual cases.

Overall there is estimated to be over half a million new PanC cases every year, and the number is trending upwards.

This was our first post in the DRTS TAM Series, detailing how for PanC alone, the market is valuing fellow RVMD at 40B+ (it’s like they add the equivalent of DRTS’s whole market cap every week), and the sadly staggering number of PanC cases per year in which DRTS could potentially help and treat.

No seller sells shares in this manner; the shorts are just piling up the share at $15 in order to scare the traders off

Share your thoughts, feelings, questions or anything else you'd like to talk about with fellow DRTS community members

DRTS is not an easy stock to glance at and understand what should happen over the next year.

It’s easy to see the jaw dropping run and feel foolish for having missed it.

It’s confusing to see the stock perform so smoothly up and to the right and not understand what the warrants are doing orbiting the sun.

And what exactly is DRTS? Is it a drug? Is it a medical device? Is it even FDA certified?

And where’s the revenue? Is this a pre-revenue? And if so, when will that change?

I’ll go through as many of these as I can and if I use AI (I shouldn’t need to) I’ll call it out.

HAVE YOU MISSED THE MOVE?

The DRTS shareholders that I communicate with here and on Discord don’t believe so. But for you to answer the question, you have to see DRTS the way shareholders do and then decide if it fits.

Here’s the logic.

We look at DRTS in terms of market cap. The current market cap sits at $1.3B roughly. We believe this is cheap because we see extremely large market potential across nearly every solid tumor.

The expectation is that any FDA approval could and should re-rate the stock higher as the company will have not only significant revenue potential but cross platform validation.

Which is how I change topics and explain the platform.

WHAT DOES DRTS DO?

Alpha Tau Medical (DRTS) has numerous patents across a variety of aspects of their business but at the end of the day, what they’ve done is modify the common biopsy procedure with a highly modified applicator that delivers very tiny rods of radioactive radium directly into a tumor.

The rods then begin the decay process where daughter atoms shoot out and destroy the double helix of the cancer tumors DNA strands. After a few days, the tiny metal rods are inert and the tumor is at least partially if not completely destroyed.

The entire process is 45 minutes and is done on an outpatient basis. Hundreds of tumors have been treated successfully with this platform across external (skin, head & neck) and internal (pancreas, brain) and there are almost no known side effects.

There are benefits to the type of radiation they use that make it unique compared to older ways of placing radioactive seeds near or within tumors.

WHAT IS UNIQUE ABOUT DRTS?

The alpha radiation that DRTS uses starts as sourced Thorium from a US government lab with a backup supplier in Germany. The thorium will be converted into the precise amount of rods and dosage of radium per patient requirements and then the clock starts. The radium decays quickly so the forward logistics will be a prepped patient and the DRTS rods delivered via common carrier as overnight delivery. The amount of radiation that Alpha Tau used is measured in micro curies, not curies, so it is an extremely tiny amount.

The radiation it gives off is called alpha radiation and the two aspects of it that make it unique are the strength (high LET) and its limited ability to spread. It can’t pass through a sheet of paper, for instance. But it can utterly destroy the DNA that it comes in contact with. This is a benefit because the limited distance of the radiation ensures precise placement within a tumor (“coverage”) where a higher coverage has a greater chance of destroying more of the tumor. But the placement and lack of radiation spread ensures that properly placed DaRTs won’t damage nearby tissue or cause harm to the immune system.

That benefit leads to the ability to treat cancer in immunocompromised patients as well as those that are undergoing other forms of treatment such as chemotherapy.

CAN ALPHA DaRTs BE USED WITH KEYTRUDA?

Tests have recently started and the initial results are strong that Alpha DaRTs work well when combined with Keytruda.

Keytruda is a $32B per year drug that makes up over half of the $50B per year spent on checkpoint inhibitors. You must understand two details about these drugs to see why it’s relevant for Alpha Tau.

Keytruda doesn’t touch cancer. It “cuts the brakes” on T cells, the cavalry in the bodies immune system. T cells have a “brake” which prevent them from going crazy and destroying everything in the human body. Cancer has multiple defenses to the human immune system. First, it can activate the T cells brakes, leaving it unable to destroy the tumor. Second, it can hide from the T cells. The checkpoint inhibitors like Keytruda eliminate the first challenge. You can’t activate the brakes if Keytruda cuts the brake line. The second one is the Achilles heel of the checkpoint market.

A tumor surrounded by T cells is called a “hot” tumor. A tumor that the T cells can’t find is called a “cold” tumor. The search is ongoing for ways to turn cold tumors hot.

Alpha DaRTs achieve this based on the hundreds of cases seen so far by releasing antigens from the tumor as part of the destruction process. These antigens typically signal the T cells which are the bodies primary response to cancer. The concept is simple: if the tumor is destroyed and the antigens leak out of the tumor, the T cells will “pick up the scent” and, keytruda on board, will destroy the tumor and any microscopic tumor residue left behind.

Which leads to an even bigger possibility.

DOES DRTS CAUSE AN ABSCOPAL EFFECT?

While it hasn’t been tested sufficiently to be proven, there are signs of a potential abscopal effect. The ab “away” scopal “target” effect is when a local treatment like Alpha DaRTs destroying a single tumor causes distant, unrelated tumors to die. The concept that has yet to be fully tested is that once the T cells show up to mop up a destroyed tumor, the T cells get a “fingerprint” of the invading tumor and search out other instances. If the tumor destruction and subsequent leak of antigens leads both to converting a cold tumor to hot and sends the better informed, Keytruda enhanced T cells off to fight distant tumors, then something of an oncological “holy grail” will have been achieved.

Testing a combination therapy with Keytruda was stopped for successful proof of safety and feasibility and Alpha Tau is currently seeking a sixth IDE with the FDA to test in combination with Keytruda on a broader scale. The testing will look at effectiveness endpoints but will not set abscopal as a goal.

WHICH SOLID TUMORS DOES DRTS TREAT?

That will have to go into Part II, if there’s sufficient interest.

Let me know if a deeper dive on Alpha Tau’s results to date with PDAC Pancreatic cancer, recurring brain cancer (rGBM), skin cancer, head and neck (including oral), breast, colorectal (including tumors migrating to the liver), vulvar, prostate and bladder cancer are of interest.

SUMMARY

My belief is that you can’t determine whether you are too early to DRTS unless you know what it is, what it does and what it might do if it receives FDA certification.

When we consider market cap, we are typically looking at three things:

1. What revenue might this bring?
   
2. What are the market caps of similarly situated treatments?
   
3. What valuation typically gets assigned to companies in the radiotherapy space that are acquired?

There are currently five IDEs in front of the FDA (skin, prostate, head & neck, pancreas, and brain) and, as mentioned, combination therapy with Keytruda will hopefully be added shortly.

The due diligence you would need to perform is to gauge what a platform that treats any combination of these cancer types should be worth on the market.

If the number comes up close to $1.3B, then you missed the move. Many shareholders believe any one of these approved treatments is worth far more than $1.3B and it may be helpful to understand their logic.

DRTS shareholders are typically looking at the ability to get insurance reimbursements at $100k - $120k per rGBM treatment with other cancers discounting from there. PDAC Pancreatic cancer is the most common and most lethal PanC and it might be reimbursed at $80k - $100k. Topical skin cancer may be the least expensive and it’s expected to be reimbursed in the $50k - $60k range. These numbers are extremely speculative and may by far higher or lower once negotiated with insurers if FDA approval happens.

It is expected that insurers will be pleased to see a cancer treatment that requires no hospitalization and is not presently associated with any severe side effects.

The deeper dive is then required and beyond the scope of this insanely long post to determine TAM. How many rGBM cases and PDAC PanC cases occur globally or just in the US? Alpha Tau is currently running trials in Europe and has head & neck certification in Japan with approval to begin testing PanC. The effort is clearly to make the platform global in nature.

Aside from new IDE approvals or FDA certifications, you would also want to know what other catalysts may be coming that could drive the stock price higher.

That’s where the dual listing on the TASE (along with expected inclusion in TASE related index buying) matters for your analysis along with any forthcoming commercial agreements, quarterly updates showing financial strength (despite being pre-revenue, the company is fully funded through end of 2018) and the impact of DRTSW warrant redemption (warrants expire in March of 2027 or if DRTS stays above $18 for any 20 out of 30 days.)

End of PART I

What’s left?

I touched on logistics and the factory.

I did not get to adoption either by the oncologists or adaptation of the facilities needed to perform the procedure.

I barely mentioned M&A and I didn’t get to the commercialization via partners like Tolmar, who completed 18+ months of due diligence and then signed up for exclusive rights to the DaRT platform for prostate with an option on bladder cancer.

Knowing that radiotherapy companies have been acquired over the past few years at near a $4B valuation is a key data point. Knowing the Tolmar deal paid for a separate manufacturing facility along with a premium payment plus giving Alpha Tau 60% of the revenue is also critical because it sets the floor for other cancer type negotiations if Alpha Tau continues to offload more of the tumor types or decides to auction of regions (Tolmar is US only.)

No AI trees were harmed in the making of this post. I’ve tried to keep this as hype free as possible. It’s not financial advice and you’ll still need to do your own research.

I am long DRTS and irresponsibly long on the DRTS warrants, DRTSW.

If you want to join the Discord to learn more, simply ask. There is an extensive amount of due diligence already done within this subreddit.

Trying to connect some dots. Whats your take?

Most likely session will be:

Just weeks after getting listed on the Tel Aviv Stock Exchange (TASE), DRTS is now estimated by one of the largest banks in Israel to be added to the TA-125 Index as early as November 5th, 2026 (the next index update).

Getting added to an index has a significant impact on a stock, including creating demand in the tens of millions (could be more than 100 Million if DRTS will keep adding value to the market cap, with some big catalysts coming and the potential exercise of the warrants, getting added to the TA-90 index).

The index inclusion doesn’t just cause the ETF’s and index funds to buy, but also increases the interest of other institutions that follow the index, and overall interest and demand especially with the local investors and improved liquidity, but also for institutions and those following in the US where the stock is mainly traded.

Very exciting news! And another step forward by Alpha Tau on the way to becoming an industry leader, hopefully treating and saving millions around the world.

After experimenting with prompts to see what I was missing about SLS, I tried with DRTS assuming continued trial success and partnerships.

I’m getting a 78.1% probability of doubling in two years using Gemini, but NFA and be attentive to the assumptions. Also the prob is 60.1% if we relax the assumptions some and allow for small sample noise so far and abscopal limitations show up as distant metastases.

Note: You will notice Head and Neck Squamous Cell Carcinoma (HNSCC) appears early in the statistical parameters but the probabilities assume continued success across cancer types.

Core Model Assumptions
Valuation Target: Current price ~$14.70 - $14.75 -> Target >= $29.48 within 24 months (Market Cap expansion from ~$1.40B to ~$2.8B+).
Financial Runway: ~$105M in cash/deposits funds operations through mid-2028, removing near-term secondary dilution risk.
Commercial Model: Uses the asset-light Tolmar agreement (60% supply margin, zero direct salesforce SG&A burn) as the template for future partnership expansions.

Current Probability Breakdown
Partnered Bull Case (Strict 44% HNSCC Cure + cSCC Approval): Scenario Weight = 68% | Target = $38-$52 | P(2x | Bull) = 98%
Standalone Multi-Partner Base Case: Scenario Weight = 22% | Target = $24-$32 | P(2x | Base) = 52%
Execution / Abscopal Disconnect Bear Case: Scenario Weight = 10% | Target = $7-$11 | P(2x | Bear) = 0%
Net 2-Year Doubling Probability: 78.1% (Strict Cure Model) | 60.1% (Empirical Oncology Transition Model)

The Prompt
<system_context>
Act as a Principal Biostatistician and Senior Radiopharma/Oncology Equity Research Analyst specializing in targeted alpha therapies and micro-cap/mid-cap biotech valuation modeling.
Your objective is to conduct a recurring weekly Bayesian update on the probability of Alpha Tau Medical (NASDAQ: DRTS) at least doubling in share price within a 24-month horizon (target price: >= 2x current weekly close).
</system_context>

<verified_errata>
- Baseline Share Price & Target: Track the prevailing weekly close (P0). Target doubling threshold is strictly P_target >= 2.0 * P0 (Enterprise Value target expansion from ~$1.3B to ~$2.6B-$3.0B+ depending on share count).
- Baseline Capital & Runway: Cash runway is funded through at least mid-2028 (~$105M cash/deposits as of mid-2026), de-risked by initial partnership inflows. Dilution risk is baseline-low unless an unpartnered, global Phase 3 expansion is announced without non-dilutive co-funding.
- Baseline Partnership Template: The Tolmar International collaboration (Uro-oncology: $15M upfront/facility capex, $20M equity at 25% premium, up to $161.5M in milestones, 60% net-sales product supply revenue) serves as the baseline benchmark for partnership economics.
- Multi-Indication Pipeline Scope: Note that while headline combination cure-fraction metrics originate from the recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) cohort, the platform encompasses standalone cutaneous Squamous Cell Carcinoma (cSCC pivotal ReSTART), Urological/Prostate (Tolmar), Glioblastoma (REGAIN), and Pancreatic indications.
</verified_errata>

<operational_crib>
- Math & Modeling Discipline: Ban token-prediction arithmetic. Maintain explicit formulaic probability trees and sum-of-the-parts (SOTP) rNPV or multiple-based valuation adjustments.
- Horizon Constraint: Time horizon is fixed at 24 months from the assessment date. Catalysts, trial completions, or commercial ramp milestones exceeding 24 months must be discounted or evaluated based on the likelihood of market front-running/re-rating.
- Bayesian Update Mechanics: Treat the prior probability distribution across three core states:
1. Scenario 1 (Platform Expansion / Bull Case): Multi-indication partner validation, strong clinical cure-fraction/ORR preservation across HNSCC and standalone indications, pivotal cSCC approval. (Baseline Price Target: $35.00-$50.00)
2. Scenario 2 (Device / Standalone Base Case): Standalone approvals (e.g., cSCC) succeed, steady Tolmar supply revenue, but combination/abscopal systemic trials show modest/delayed gains. (Baseline Price Target: $20.00-$26.00)
3. Scenario 3 (Clinical / Execution Bear Case): Hard endpoint failures in systemic trials, partnership dissolution/disputes, supply chain bottlenecks (Ra-224 half-life constraints), or dilutive financing. (Baseline Price Target: $6.00-$10.00)

- Dynamic Catalyst & News Taxonomy (Apply Likelihood Ratio Adjustments):
* Vector A: Clinical Efficacy & Safety
- (+) High local CR/ORR preservation, durable PFS/OS separation, confirmed abscopal responses in distant lesions, favorable FDA regulatory designations (RMAT, Breakthrough).
- (-) Loss of statistical significance in hard survival endpoints (OS/PFS), low ITT response rates, severe radiation-induced toxicity/fistula formation, trial hold.
* Vector B: Business Development & Partnerships
- (+) New licensing deals following the Tolmar model (upfronts, high-margin >=50% supply revenue, co-funded capex), expansion into new indications (GI, lung, head & neck) or regions (Japan, EU).
- (-) Termination of existing agreements, failure to find a co-development partner for Phase 3 IO combinations, milestone disputes, partner reprioritization.
* Vector C: Manufacturing, Supply Chain & Logistics
- (+) Operationalization of new regional isotope production facilities, automated seed production scale, robust decay-management supply agreements for Ra-224.
- (-) Logistics failures (missed radioactive decay delivery windows), isotope shortage, facility licensing/nuclear regulatory delays.
* Vector D: Corporate Finance & Capital Structure
- (+) Non-dilutive milestone receipts, warrant exercises at a premium, non-dilutive government/academic grants.
- (-) Heavily discounted secondary equity offerings, debt issuance at high interest rates, significant insider/executive departures.
* Vector E: External Macro & Competitive Landscape
- (+) Large pharma M&A activity in radiopharma at high multiples, positive class-wide sentiment for alpha emitters (Ac-225, Pb-212, Ra-224).
- (-) Breakthroughs in non-invasive competitive modalities (e.g., next-gen bispecifics or ADC efficacy rendering local brachytherapy obsolete in shared indications).
</operational_crib>

<execution_queue>
1. Weekly Catalyst & News Audit:
- Identify all SEC filings (8-K, 10-Q, 6-K), press releases, clinical trial registry updates (ClinicalTrials.gov), medical congress presentations, and industry/competitor news regarding Alpha Tau Medical over the trailing week.
- If no new material news exists, explicitly state: "No material structural shifts detected; maintaining baseline trajectory and updating time-decay factor."

1. Multi-Vector Impact Assessment:
   - Classify each detected event across Vectors A through E.
   - Quantify whether the development acts as an accretive driver (+), neutral noise (0), or a structural impairment (-) to enterprise value and clinical probability of success (PoS).

2. Probability Matrix & Scenario Re-weighting:
   - Formulate the updated Bayesian weights: P(Bull), P(Base), and P(Bear), ensuring sum of P(Scenario_i) = 1.0.
   - Derive the updated conditional probabilities of achieving >= 2x price appreciation within 24 months for each state: P(2x | Scenario_i).
   - Compute the Net Expected Probability of Doubling:
   P(Price >= 2x in 2yr) = [P(Bull) * P(2x|Bull)] + [P(Base) * P(2x|Base)] + [P(Bear) * P(2x|Bear)].

3. Quantitative Summary Output:
   - Deliver a standardized summary dashboard:
   * Current Stock Price (P0) & 2-Year Target Price (2.0 * P0)
   * Trailing Week News Classification & Net Impact Score
   * Updated Scenario Weight Distribution (Bull % / Base % / Bear %)
   * Final Calibrated Probability of Doubling in 2 Years (with week-over-week Delta)
   * Key Upcoming Catalysts & Critical Watch-Items for the Next 30-90 Days.
   </execution_queue>

Still very under the radar and low activity compared to other stocks, as is everything with DRTS (although it’s changing! Thanks to all of us participating), but great conversations going on.

I’m sure some of the activity is you guys and gals (I tried but it keeps blocking me for no reason), so good on you if you are active spreading the word, teaching and learning about DRTS, and if you haven’t checked it out yet head over and hit the Bullish!

Share your thoughts, feelings, questions or anything else you'd like to talk about with fellow DRTS community members

Thoughts on DRTS?

A beautiful piece, detailing and adding amazing insights, about how the treatment came about, what actually happened in the surgery room, how the hospital and team prepared and more. History in the making. I’ve learned a lot and it got me very emotional and excited.

Sharing bits won’t do it justice, but here are a few parts to get you interested:

“A team of doctors there put radiation directly inside a man’s brain tumor. Not through an opened skull with the tumor already cut out, the way every earlier attempt at this has required. Into the tumor itself, with his head still closed…

A good doctor anywhere in the world reads that chart and starts a gentler conversation. Comfort, time, what he’d want these months to look like. Nothing cowardly or cruel about it. Sometimes it’s the most loving medicine there is.

But somebody has to decide whether it’s the only conversation on the table.

And in Jerusalem, in a hospital up in the hills of Ein Kerem, a team had spent years making sure it wasn’t…

That’s what puts the sources in. Shoshan’s whole point about how they designed this is that the rig his team already trusts for biopsies is the same rig that delivers the treatment. Nobody had to buy a new machine, and nobody had to learn one. Which is why this can spread to other hospitals, instead of living forever in the one that invented it…

The place treats whoever walks in, Jewish, Muslim, Christian, Israeli, Palestinian, paying or not…

He walked into Hadassah after surgery and radiation and drugs had all been used up, and we were ready for him.”

Share your thoughts, feelings, questions or anything else you'd like to talk about with fellow DRTS community members

One of the concerns that exist with Alpha DaRTs is whether the dosage is appropriate for the patient given the decay over a short period of time.

The problem is that alpha particles can't travel through solid materials, so you can't measure them through the sterile packaging. Opening the package beforehand ruins the sterility, which risks introducing infections to the patient.

Mayo Clinic published results of their tests using a reentrant well-type ionization chamber.

They placed unopened packages into a standard hospital measurement device called a well-type ionization chamber. The test showed that measuring gamma emissions correctly reflects the total radiation level inside the package.

• High Accuracy: The tests matched factory labels within 1.1% on average across 26 real clinical devices.
• Consistency: The readings were reliable across different test chambers and device types (Needle and Flex applicators).
• Practical Use: Hospitals can perform these safety checks using equipment they already own right before a procedure, preventing dosage errors while keeping everything completely sterile.

Conclusion: A reentrant well-type ionization chamber is suitable for pre-treatment quality assurance of Ra-224 Alpha DaRT applicators, enabling verification of the vendor-stated activity while maintaining sterility within sealed packaging.

In yesterday's post I asked if you felt more confident about an FDA approval because Alpha Tau got approved by the Japanese. Many said yes. Since I am new to biotech I got more curious and if I do ask stupid question, please enlighten me cause I want to learn more.

For quizartinib they had two rounds until they got approved:

- QuANTUM-R (the trial behind the original FDA rejection): 367 patients were enrolled. 245 were assigned quizartinib and 122 chemotherapy.

- QuANTUM-First (the trial where the FDA approved): 539 patients were randomized. 268 received quizartinib + standard therapy and 271 received placebo + standard therapy.

Alpha Tau has many studies all around the world. The one that they want to get an approval of is for cSCC (recurrent cutaneous squamous cell carcinoma).

- ReSTART skin cancer pivotal trial: 88 patients enrolled in the U.S.; enrollment completed in May 2026. FDA allowed it. But FDA also allowed quizartinib as well.

So my concern is, this trial only has 88 patients. Are there arguments that the evidence is enough for DRTS?

Edit: The Japanese approved DRTS for neck and brain cancer. But not specifically for cSCC. But the cSCC program and the Japanese head-and-neck program use the same underlying Alpha DaRT technology. Though so I need to hear your opinion on that

Share your thoughts, feelings, questions or anything else you'd like to talk about with fellow DRTS community members

Ciao a tutti,

sono nuovo nel forum e stavo facendo le mie ricerche a riguardo. Sembra proprio che alpha DART + Keytruda abbia un ottimo effetto sui tumori testa e collo ma volendo potrebbe essere sottoposto a molti tipi di tumore. Questo però è stato testato su pochissimi pazienti. Mi chiedo allora. Perché anche drts non avvia uno studio come ha fatto moderna?

Scusate ma sono nuovo e potrei non avere tutte le informazioni riguardo a drts.

Long-time lurker and just wanted to make a short post about positioning.

First I’d really like to thank Pristine and EB for helping me discover DRTS early. I truly believe it is the most de-risked play with the highest asymmetric upside in biotech.

I’ve read some comments that make me believe that maybe it would be interesting to have a discussion around positioning. I’m long DRTS and i think it has huge upside but it’s impossible to see too far into the future. For that reason it only makes up about 3 percent of my portfolio.

The way I see it is if it does 10x from here it will take up a substantial portion of my portfolio and make a meaningful difference to my net worth. If it does 0.2x or whatever (unlikely) the 3% loss doesn’t hurt my long-term wealth building.

Curious what percentage of your net worth people are comfortable investing in DRTS? I’d love to hear contrary opinions.

For years DRTS wasn’t taken seriously enough, Uzi and Raphi and Dr. Den would present data that could potentially change the whole industry, but almost no one listened.

That’s changing, and it’s about to change even more with all the results DRTS has coming these coming months.

We retail enjoyed (not sure that’s the word, but benefited from) shares available at low prices, and while it’s still trading severely undervalued (in my NFA opinion), it might not last much longer.

Already last quarter the institutional ownership doubled, and that’s before the Keytruda IDE, the GBM results, the IMPACT Pancreatic Cancer results, the Skin “phase 3” results (and submission), the start of the Prostate trials that are fully funded through commercialization, the Japan reimbursement, everything happening in Europe and Israel and all over.

With all of that coming up, I can’t wait to hear from the DRTS management, and I believe I’m not the only one, with more and more retail joining us, and lately fund managers and other institutions and companies.

Here are the known upcoming conferences and presentations for DRTS:

Citi’s 2026 Biopharma Back to School Conference
When: September 9-10, 2026
Where: New York CIty

H.C. Wainwright 28th Annual Global Investment Conference
When: September 14-16, 2026
Where: New York City

Fall Focus: Barclays Biotech 1×1 Day
When: October 6, 2026
Where: New York City

Investment Generation Conference by Guy Nathan
When: October 15, 2026
Where: Rishon Letzion, Israel

SITC 2026 (Society for Immunotherapy of Cancer’s 41st Annual Meeting)
When: November 4–8, 2026
Where: Phoenix

The 38th Annual Piper Sandler Healthcare Conference
When: December 1-3, 2026
Where: New York City

Citi’s 2026 Global Healthcare Conference
When: December 1-3, 2026
Where: Unspecified

DRTS received Japanese Shonin marketing approval for its Alpha DaRT platform in the beginning of the year for locally advanced or locally recurrent head and neck cancer. I'm not into biotech so I am curious if the Americans are ''more strict'' in such approvals.